Drug Profile

BH 30236

Alternative Names: BH-30236

Latest Information Update: 18 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BlossomHill Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Clk dual-specificity kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Acute myeloid leukaemia
New Molecular Entity Yes

Highest Development Phases

Phase I Myelodysplastic syndromes; Myeloid leukaemia

Most Recent Events

11 Jun 2026 Pharmacokinetics, efficacy and adverse events data from a phase I/Ib trial in Acute myeloid leukemia released by BlossomHill Therapeutics
12 May 2026 BH 30236 receives Orphan Drug status for Acute myeloid leukaemia in USA
12 May 2026 Pharmacokinetics, efficacy and adverse events data from a phase I/Ib trial in Acute myeloid leukemia released by BlossomHill Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com